
Uracil: Pyrimidine-2,4(1H,3H)-dione. $C_4H_4N_2O_2$ 112.09 Lamivudine-uracil derivative: 1-[(2RS,5SR)-2-(Hydroxymethyl)-1,3-oxathiolan-5-yl]uracil. C₈H₁₀N₂O₄S 230.24 Cytosine: 4-Aminopyrimidin-2(1H)-one. $C_4H_5N_3O$ 111.10 Lamivudine-S-sulfoxide: 1-[(2R,3S,5S)-2-(Hydroxymethyl)-1,3-oxathiolan-5-yl]cytosine S-oxide. C₈H₁₁N₃O₄S 245.26 Lamivudine-*R*-sulfoxide: 1-[(2*R*, 3*R*, 5*S*)-2-(Hydroxymethyl)-1,3-oxathiolan-5-yl]cytosine S-oxide. C₈H₁₁N₃O₄S 245.26 Lamivudine carboxylic acid: (2RS,5SR)-5-(Cytosine-1-yl)-1,3-oxathiolane-2-carboxylic acid. $C_8H_9N_3O_4S$ 243.24 Lamivudine diastereomer: 1-[(2*S*,5*S*)-2-(Hydroxymethyl)-

Mode: LC Detector: UV 254 nm **Column:** 4.6-mm \times 5-cm; 5-µm packing L1 Column temperature: 30° Flow rate: 1 mL/min Injection size: $20 \,\mu L$ System suitability Sample: Standard solution Suitability requirements Relative standard deviation: NMT 1.5% Analysis Samples: Standard solution and Sample solution Calculate the percentage of $(C_{14}H_{18}N_6O)_2 \cdot H_2SO_4$ in the portion of Abacavir Sulfate taken:

Result = $(r_U/r_s) \times (C_s/C_U) \times 100$

1,3-oxathiolan-5-yl]cytosine. C₈H₁₁N₃O₃S 229.26 Salicylic acid: 2-Hydroxybenzoic acid. 138.12 $C_7H_6O_3$

Abacavir Sulfate



670.74 $(C_{14}H_{18}N_6O)_2 \cdot H_2SO_4$ 2-Cyclopentene-1-methanol, 4-[2-amino-6-(cyclopropylamino)-9H-purin-9-yl]-, (1S-cis)-, sulfate (salt) (2:1); (1*S*,4*R*)-4-[2-Amino-6-(cyclopropylamino)-9*H*-purin-9-yl]-2-cyclopentene-1-methanol sulfate (salt) (2:1) [188062-50-2].

DEFINITION

- = peak area of abacavir from the Sample solution
- = peak area of abacavir from the Standard solution
- Cs = concentration of USP Abacavir Sulfate RS in the Standard solution (mg/mL)
- = concentration of Abacavir Sulfate in the Cu Sample solution (mg/mL) Acceptance criteria: 97.0%–102.0% on the anhydrous and solvent-free basis

IMPURITIES

ΓU

rs.

Inorganic Impurities

- RESIDUE ON IGNITION (281): NMT 0.2%
- Organic Impurities
- PROCEDURE 1: RELATED COMPOUNDS

Solution A: Trifluoroacetic acid and water (0.05:99.95)

Solution B: Methanol and water (17:3)

Mobile phase: See the gradient table below.

Time (min)	Solution A (%)	Solution B (%)
0	95	5
20	70	30
35	10	90

DIM dSD

Abacavir Sulfate contains NLT 97.0% and NMT 102.0% of $(C_{14}H_{18}N_6O)_2 \cdot H_2SO_4$, calculated on the anhydrous and solvent-free basis.

IDENTIFICATION

- A. INFRARED ABSORPTION (197K)
- **B**. The retention time of the major peak of the Sample solution corresponds to that of the System suitability solution, obtained as directed in the test for Organic Impurities, Procedure 2.
- C. IDENTIFICATION TESTS-GENERAL, Sulfate (191) Sample solution: 5 mg/mL

ASSAY

• PROCEDURE

- Mobile phase: Acetonitrile, phosphoric acid, and water (20:1:180)
- Standard solution: 0.04 mg/mL of USP Abacavir Sulfate RS in water
- Sample solution: 0.04 mg/mL of Abacavir Sulfate in water
- Chromatographic system
- (See Chromatography (621), System Suitability.)

35.1	95	5
50	95	5

System suitability solution: 0.25 mg/mL of USP Abacavir Related Compounds Mixture RS in water Sample solution: 0.25 mg/mL of Abacavir Sulfate in water Chromatographic system (See Chromatography (621), System Suitability.) Mode: LC Detector: UV 254 nm **Column:** 3.9-mm × 15-cm; 5-µm packing L1 Column temperature: 30° Flow rate: 1 mL/min Injection size: 20 µL System suitability **Sample:** System suitability solution Suitability requirements **Resolution:** NLT 1.5 between abacavir and *trans*abacavir Analysis Sample: Sample solution Calculate the percentage of each impurity in the por-

tion of Abacavir Sulfate taken:

Result = $(r_U/r_T) \times 100$

- = peak area of each impurity from the Sample ٢u solution
- = sum of the areas of all the peaks from the ΓŢ Sample solution